Inactivating mutations in the BCL11A gene are associated with sickle cell disease and β-thalassemias (10–12), and it was subsequently shown that BCL11A is a master regulator of fetal haemoglobin switching (13,14). This evidence concerns the gene BCL11A and sickle cell disease.